NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.840
-0.060 (-3.16%)
Nov 7, 2025, 4:00 PM EST - Market closed
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,352,424
Market Cap
32.07M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 7 | 0 | - |
| Jun 30, 2024 | 7 | 0 | - |
| Jun 30, 2023 | 7 | -10 | -58.82% |
| Jun 30, 2022 | 17 | 0 | - |
| Jun 30, 2021 | 17 | 0 | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NNVC News
- 2 days ago - NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT - Accesswire
- 4 days ago - NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd - Accesswire
- 9 days ago - Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive - Accesswire
- 11 days ago - NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 - Accesswire
- 16 days ago - In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides - Accesswire
- 18 days ago - A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus - Accesswire
- 23 days ago - NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses - Accesswire
- 5 weeks ago - NanoViricides, Inc. Has Filed its Annual Report - Accesswire